Piramal Imaging to release florbetaben findings

10/17/2013 | PRNewswire

Piramal Imaging will release data from studies of the company's PET imaging agent F-18 florbetaben at the 2013 Annual Congress of the European Association of Nuclear Medicine in France. Florbetaben is being evaluated by the FDA and the European Medicines Agency for the detection of beta-amyloid plaques in patients with Alzheimer's disease and other neurodegenerative conditions.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI